The FDA’s chief is the agency. COVID-19 Vaccine For winter.
In August 2024, the US Food and Drug Administration approved an updated mRNA covid vaccine. Current variationsand has also approved an updated Novavax vaccine.
However, FDA commissioner Dr. Marty McCurry has expressed doubts about whether it is necessary for the 2025-2026 season.
Research suggests that the risk of dementia can be immersed in common vaccines
“We’re looking. We can’t comment on any particular application. You know, there are a lot of applications in these booster shots,” McCurry told CBS News Tuesday.
In August 2024, the US Food and Drug Administration approved an updated mRNA covid vaccine to protect against current variants, as well as an updated Novavax vaccine. (istock)
“I don’t think there’s data, and I’d like to see good data rather than filling that blank with opinions,” he added.
McCurry also mentioned the “public trust issues” surrounding Covid boosters, noting that many health workers from last season opted out of receiving them.
Influenza vaccines associated with higher infections say early studies
The FDA chief has also expressed concern about the lack of data to support Novavax’s Covid vaccine and is calling for more research into its effectiveness before approval.
“The Big Novavax 2020-2021 study ruled out people Innate immunity against Covid. Today, there is a wide population immunity, and the big question is, does it provide benefits? ”
FDA Commissioner Dr. Marty McCurry has expressed doubts about whether it is necessary for the 2025-2026 season. (Getty Images)
“Without new formulations and research into products, we cannot provide honest, evidence-based answers to that question.”
Novavax posted an update on the FDA’s request for additional clinical trials on Tuesday.
Click here to get the Fox News app
“It’s my general feelings, not this particular product, and for detailed products, discussing drugs in general needs to know if they’re working today so they can recommend them,” McCurry told CBS News Tuesday.
Click here to sign up for our health newsletter
The Centers for Disease Control and Prevention (CDC) is also considering narrowing down recommendations A wide range of covid vaccines It starts from 2025-2026.
The Centers for Disease Control and Prevention (CDC) is also considering narrowing down widespread recommendations for Covid vaccines from 2025 to 2026. (Reuters/Dad Luvik/Illustration/File Photo)
In its April report, the agency offered three options: Covid booster. To maintain a “universal vaccine policy” for everyone over six months, it is recommended only for groups at high risk for severe covid disease, or use risk-based recommendations up to age 64 and switch to universal recommendations at age 65.
The main risk factors for severe illness include underlying age progression Symptoms Pregnancy, the CDC said.
For health articles, please visit www.foxnews.com/health
Those I work in healthcare Alternatively, those living in long-term care facilities are at a higher risk of exposure.
